- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05923541
RD13-02 for Patients With r/r CD7+ T Cell Hematologic Malignancies
June 26, 2023 updated by: KeshuZhou, Henan Cancer Hospital
Clinical Study on Efficacy, Safety and Cytopharmacokinetics of RD13-02 Cell Injection in the Treatment of Patients With Recurrent or Refractory CD7-positive Hematologic Malignancies
This is a single-arm, open-label, single-center, phase I study.
The primary objective is to evaluate the safety of CD7 CAR-T therapy for patients with CD7-positive relapsed or refractory T-ALL/LBL, and to evaluate the pharmacokinetics of CD7 CAR-T in patients.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
10
Phase
- Early Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Shu Ke Zhou, Dr.
- Phone Number: 13674902391
- Email: drzhouks77@163.com
Study Locations
-
-
Henan
-
Zhengzhou, Henan, China, 450003
- Recruiting
- Henan cancer hospital
-
Contact:
- Shu Ke Zhou, Dr.
- Phone Number: 13674902391
- Email: drzhouks77@163.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Age 3-70
- Diagnosis of r/r T-ALL/LBL.
- CD7 positive expression
- Bone marrow lymphoblasts ≥5% by morphologic evaluation at screening
- Creatinine clearance (as estimated by Cockcroft Gault) ≥ 60 mL/min, Serum alanine aminotransferase(ALT)/aspartate aminotransferase(AST) < 3×upper limit of normal, Total bilirubin < 1.5×upper limit of normal or ≤1.5mg/dl
- Left ventricular ejection fraction ≥ 50% .
- Baseline oxygen saturation ≥ 92% on room air.
- ECOG performance status of 0 to 2.
- The estimated survival time is more than 3 months.
- Subjects or their legal guardians volunteer to participate in the study and sign the informed consent.
Exclusion Criteria:
- Subjects with concomitant genetic syndromes associated with bone marrow failure states.
- Isolated extramedullary lesions
- Subjects with some cardiac conditions will be excluded.
- With uncontrolled active central nervous system leukemia (CNSL), cerebrospinal fluid grade CNS3.
- History of traumatic brain injury, consciousness disturbance, epilepsy, cerebrovascular ischemia, and cerebrovascular hemorrhagic disease, which might compromise the ability of the subject to compliance with the obligations under the protocol.
- History of malignancy other than non-melanoma skin cancer or carcinoma.
- Primary immune deficiency.
- Presence of uncontrolled infections.
- Sujects with some anticancer therapy before CAR-T infusion will be excluded.
- Active uncontrolled acute infections.
- Known history of infection with human immunodeficiency virus (HIV); active or latent hepatitis B, hepatitis C and syphilis.
- Subjects who are receiving systemic steroid therapy prior to screening.
- Subjects with acute graft-versus-host disease (GvHD)
- Having received live/attenuated vaccine within 4 weeks prior to screening.
- History of allergy to any component of the cell therapy product.
- Pregnant or breastfeeding women
- Any other issue which, in the opinion of the investigator, would make the sujects ineligible for the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: RD13-02 cell infusion
drugs use generic name : RD13-02 CAR-T cell injection; dosage form : Cell injection; dosage : 2×10^8 CAR+ T cells; frequency : Once.
|
Universal CAR-T cells targeting CD7
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall response rate, ORR
Time Frame: Evaluate at 4 weeks after CAR-T infusion
|
The proportion of patients with CR (complete response) /CRi (complete response with incomplete blood cell recovery) and PR (partial response).
|
Evaluate at 4 weeks after CAR-T infusion
|
Overall response rate, ORR
Time Frame: Evaluate at 8 weeks after CAR-T infusion
|
The proportion of patients with CR (complete response) /CRi (complete response with incomplete blood cell recovery) and PR (partial response).
|
Evaluate at 8 weeks after CAR-T infusion
|
Overall response rate, ORR
Time Frame: Evaluate at 12 weeks after CAR-T infusion
|
The proportion of patients with CR (complete response) /CRi (complete response with incomplete blood cell recovery) and PR (partial response).
|
Evaluate at 12 weeks after CAR-T infusion
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Event-free survival, EFS
Time Frame: Up to 1 years after CAR-T infusion
|
The time from first achieving CR/CRi to relapse or death
|
Up to 1 years after CAR-T infusion
|
Overall survival, OS
Time Frame: Up to 1 years after CAR-T infusion
|
The time from CAR-T infusion to death due to any cause
|
Up to 1 years after CAR-T infusion
|
Overall response rate with MRD-negative, MRD-ORR
Time Frame: Up to 1 years after CAR-T infusion
|
Proportion of patients achieving CR/CRi who is MRD-negative in bone marrow
|
Up to 1 years after CAR-T infusion
|
Duration of remission, DOR
Time Frame: Up to 1 years after CAR-T infusion
|
The time from CR/CRi and PR to disease relapsed or death due to disease progression after CAR-T infusion
|
Up to 1 years after CAR-T infusion
|
The proportion of patients who receive hematopoietic stem cell transplantation
Time Frame: Up to 1 years after CAR-T infusion
|
The proportion of subjects who achieved remission after infusion who received HSCT
|
Up to 1 years after CAR-T infusion
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
June 30, 2023
Primary Completion (Estimated)
June 7, 2025
Study Completion (Estimated)
June 7, 2026
Study Registration Dates
First Submitted
June 7, 2023
First Submitted That Met QC Criteria
June 26, 2023
First Posted (Actual)
June 28, 2023
Study Record Updates
Last Update Posted (Actual)
June 28, 2023
Last Update Submitted That Met QC Criteria
June 26, 2023
Last Verified
June 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BHCT-RD13-02-11
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hematologic Malignancies
-
Cooperative Study Group A for HematologyCompletedHEMATOLOGIC MALIGNANCIESKorea, Republic of
-
Fondazione EMN Italy OnlusCompletedHEMATOLOGIC MALIGNANCIESItaly
-
Washington University School of MedicineRecruitingPediatric Hematologic MalignanciesUnited States
-
Medical College of WisconsinCompletedMalignancies, HematologicUnited States
-
Sinocelltech Ltd.RecruitingRelapsed or Refractory Hematologic MalignanciesChina
-
Vanda PharmaceuticalsUnknownRelapsed or Refractory Hematologic MalignanciesUnited States
-
University of UtahTerminatedHigh Risk Hematologic MalignanciesUnited States
-
King Faisal Specialist Hospital & Research CenterCompletedTransplantation for Hematologic MalignanciesSaudi Arabia
-
Precision BioSciences, Inc.RecruitingHematologic Malignancy | CD19 Expressing MalignanciesUnited States
-
University of California, DavisCompletedHematologic MalignanciesUnited States
Clinical Trials on RD13-02 cell infusion
-
Xiaoyu ZhuNanjing Bioheng Biotech Co., Ltd.RecruitingNeoplasms | Hematologic Diseases | Hematologic NeoplasmsChina
-
He HuangNanjing Bioheng Biotech Co., Ltd.RecruitingNeoplasms | Neoplasms by Site | Hematologic Diseases | Hematologic NeoplasmsChina
-
Kai Lin Xu,MDNanjing Bioheng Biotech Co., Ltd.RecruitingNeoplasms | Hematologic Diseases | Hematologic NeoplasmsChina
-
MEI HENGNanjing Bioheng Biotech Co., Ltd.RecruitingNeoplasms | Neoplasms by Site | Hematologic Diseases | Hematologic NeoplasmsChina
-
He HuangCompletedHematologic MalignanciesChina
-
Min XiangUnknownT-lymphoblastic Lymphoma | T Acute Lymphoblastic LeukemiaChina
-
Jianming TanUnknownOsteochondritis of the Femoral HeadChina
-
Baylor College of MedicineUniversity of Texas, Southwestern Medical Center at DallasCompletedLeukemia | CancerUnited States
-
Hospital Universitario Dr. Jose E. GonzalezSuspendedCardiomyopathy, DilatedMexico
-
The University of Texas Health Science Center,...United States Department of Defense; U.S. Army Medical Research and Development...Active, not recruitingTBI (Traumatic Brain Injury) | Brain Injuries, Traumatic | Brain Injuries, AcuteUnited States